FLI1 Antibody

What is FLI1 and why is it significant in molecular oncology research?

FLI1 (Friend leukemia integration 1 transcription factor) is a sequence-specific transcriptional activator belonging to the ETS family of DNA binding transcription factors. In humans, the canonical protein has 452 amino acid residues with a molecular weight of approximately 51 kDa and is primarily localized in the nucleus . This protein is particularly significant in cancer research because:

• It functions as a proto-oncogene involved in cellular proliferation, differentiation, and apoptosis

• It regulates genes involved in immune response and organ morphogenesis

• It is central to the pathogenesis of Ewing sarcoma through the EWS::FLI1 fusion protein created by the t(11;22)(q24;q12) chromosomal translocation

• It serves as a marker for vascular tumors due to its expression in endothelial cells

• Aberrant FLI1 expression has been linked to poor prognosis in acute myeloid leukemia

Recent research has revealed FLI1 as a critical mediator in impairing T cell anti-tumor immunity through the regulation of kynurenine metabolism in nasopharyngeal carcinoma , expanding its significance beyond Ewing sarcoma and vascular tumors.

What are the principal differences between polyclonal and monoclonal FLI1 antibodies in research applications?

The choice between polyclonal and monoclonal FLI1 antibodies significantly impacts experimental outcomes:

Research indicates that the combination of CD99 and FLI1 polyclonal (FLI-1p) antibodies provides the most sensitive and specific test panel for the diagnosis of Ewing sarcoma/primitive neuroectodermal tumor (EWS/PNET) . While FISH techniques offer 100% specificity, they show only moderate sensitivity (50%), supporting the value of antibody-based detection methods .

Which tissues and cell types normally express FLI1, and how does this impact control selection?

Understanding the normal expression pattern of FLI1 is essential for proper experimental design:

• Endothelial cells: Consistent FLI1 expression makes it a useful marker for vascular structures and tumors

• Small lymphocytes: Express detectable levels of FLI1, requiring careful interpretation in lymphoid-rich tissues

• Hematopoietic cells: Express FLI1 as part of normal development and function

• Experimental controls: Jurkat cells (T-cell leukemia) show robust FLI1 expression and serve as positive controls for Western blotting

• Negative tissue controls: Most epithelial tissues show negligible FLI1 expression

For proper experimental design, researchers should include tissue controls such as adrenal gland, fallopian tube, placenta, and cervix when validating FLI1 immunohistochemistry . For tumor studies, angiosarcoma, PNET, and hemangiomas serve as appropriate positive controls .

How should Western blot protocols be optimized for FLI1 and EWS::FLI1 detection?

For optimal detection of FLI1 and fusion proteins by Western blotting:

• Sample preparation:

  • For nuclear proteins like FLI1, use appropriate nuclear extraction methods

  • Load recommended amounts: 30 µg whole cell lysate, 20 µg cytoplasmic extract, or 10 µg nuclear extract

  • Include positive controls (Jurkat cells) and appropriate negative controls

• Gel and transfer conditions:

  • Use reducing conditions for consistent results

  • Expected molecular weights: 51-53 kDa for wild-type FLI1, 65 kDa for EWS::FLI1 type 1, and 75 kDa for EWS::FLI1 type 3

  • PVDF membranes provide better protein retention for transcription factors

• Antibody incubation parameters:

  • Block membranes with 5% nonfat dry milk in TTBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20)

  • Dilute primary FLI1 antibodies 1:1000-1:4000 in 5% BSA in TTBS buffer

  • Incubate at room temperature for 2 hours or at 4°C overnight

  • Use appropriate HRP-conjugated secondary antibodies (typically 1:5000)

• Validation strategies:

  • Peptide competition can confirm specificity of band detection

  • For EWS::FLI1 detection, compare with known positive cell lines (TC32 for type 1, A4573 for type 3)

  • When optimizing new antibodies, test multiple dilutions to identify optimal signal-to-noise ratio

What are the critical parameters for successful immunohistochemical detection of FLI1 in tissue samples?

Successful immunohistochemical detection of FLI1 requires attention to several critical parameters:

• Tissue processing and preparation:

  • FLI1 antibodies work with both FFPE and frozen sections

  • Fine-needle aspirates and tumor touch imprints can also be evaluated

  • Heat-mediated antigen retrieval with citrate buffer (pH 6.0) is typically required for FFPE sections

• Staining protocol optimization:

  • Block endogenous peroxidases and non-specific binding sites

  • Antibody dilutions vary by product and must be optimized

  • Nuclear staining pattern is expected for FLI1

  • Avoid biotin-based detection systems if possible, as FLI1 is the first nuclear marker of endothelium that generally lacks cytoplasmic staining artifacts from endogenous peroxidases or biotin

• Interpretation criteria:

  • Positive FLI1 signal is primarily nuclear in location

  • In Ewing sarcoma, approximately 80% of cases exhibit positive immunoreactivity

  • Specificity can be confirmed by absence of signal when blocking peptide is added to antibody solution

  • Consider the natural expression in endothelial cells and lymphocytes when evaluating results

• Diagnostic application:

  • In one study, the combination of CD99 and FLI1 polyclonal antibody showed the highest sensitivity and specificity for ES/PNET diagnosis

  • Complementary FISH analysis can provide additional specificity when available

How can co-immunoprecipitation with FLI1 antibodies be optimized to study protein interactions?

Co-immunoprecipitation (Co-IP) using FLI1 antibodies provides valuable insights into protein-protein interactions:

• Nuclear extract preparation:

  • Use specialized nuclear Co-IP kits (e.g., Active Motif universal magnetic Co-IP kit)

  • Prepare fresh extracts from relevant cell lines (TC32 and A4573 for EWS::FLI1 studies)

  • Typically use 300 μg of nuclear extract per IP reaction

• Immunoprecipitation conditions:

  • Use 2-3 μg of FLI1 antibody per reaction

  • Include appropriate negative controls (mouse monoclonal IgG)

  • Protein G magnetic beads improve recovery efficiency compared to traditional agarose beads

  • Perform precipitation at 4°C with gentle rotation overnight

• Washing and elution:

  • Use stringent washing to reduce non-specific binding

  • Elute under conditions that maintain associated protein complexes

  • Consider native elution for downstream functional studies

• Analysis of interacting proteins:

  • Perform Western blot for suspected interaction partners

  • Successful examples include detection of RHA, PRPF8, SFPQ, hnRNPK, and SRSF3 in complex with EWS::FLI1

  • Consider mass spectrometry for unbiased identification of novel interactors

• Validation approaches:

  • Perform reciprocal Co-IP when antibodies are available

  • Use knockdown/knockout controls to confirm specificity

  • Correlate with other protein interaction methods (e.g., proximity ligation assay)

How can FLI1 antibodies be used to study chromatin remodeling mechanisms in Ewing sarcoma?

Recent research has revealed complex interactions between EWS::FLI1 and chromatin remodeling:

• Chromatin immunoprecipitation applications:

  • FLI1 antibodies enable mapping of EWS::FLI1 binding sites across the genome

  • Sequential ChIP (re-ChIP) can identify co-occupancy with other transcription factors

  • ChIP-seq reveals global binding patterns and motif preferences

• BAF complex interactions:

  • EWS::FLI1 has been shown to interact with the BAF chromatin remodeling complex

  • FLI1 antibodies have revealed that EWS::FLI1 modulates alternative splicing of ARID1A, a key BAF component

  • This creates a feed-forward cycle where EWS::FLI1 leads to preferential splicing of ARID1A-L, which then reciprocally promotes EWS::FLI1 protein stability

• Regulatory landscape analysis:

  • Integrating FLI1 ChIP-seq with H3K27ac ChIP-seq defines active regulatory elements

  • In bladder cancer, FLI1 and FRA1 have been identified as critical transcription factors differentially regulating the MIBC regulatory landscape

  • ChIP-SICAP (Selective Isolation of Chromatin-Associated Proteins) has enabled identification of chromatin binding partners of these transcription factors

• Methodological considerations:

  • Fixation and sonication conditions must be optimized for nuclear transcription factors

  • Include appropriate controls (input, IgG, positive and negative loci)

  • Consider dual crosslinking for improved capture of protein-protein interactions

What role does FLI1 play in immune regulation, and how can antibodies help study these mechanisms?

Emerging research has revealed FLI1's unexpected role in immune regulation:

• FLI1 in immune evasion:

  • Recent studies identified tumor-intrinsic FLI1 as a critical mediator in impairing T cell anti-tumor immunity

  • FLI1 orchestrates the expression of CBP and STAT1, facilitating chromatin accessibility and transcriptional activation of IDO1 in response to T cell-released IFN-γ

  • This regulatory cascade enhances kynurenine (Kyn) synthesis in tumor cells, fostering CD8+ T cell exhaustion and regulatory T cell differentiation

• Antibody applications in this field:

  • Monitoring FLI1 expression in both tumor and infiltrating immune cells

  • Investigating correlation between FLI1 levels and immune cell phenotypes

  • ChIP studies to identify direct FLI1 targets in immune regulatory pathways

• Therapeutic implications:

  • Pharmacological inhibition of FLI1 can obstruct the CBP/STAT1-IDO1-Kyn axis

  • This approach may invigorate both spontaneous and checkpoint therapy-induced immune responses

  • FLI1 inhibition shows potential for enhancing tumor eradication in combined immunotherapy approaches

• Technical approaches:

  • Multiplex immunohistochemistry to simultaneously visualize FLI1 and immune markers

  • Flow cytometry with FLI1 antibodies to assess expression in immune subpopulations

  • Single-cell approaches to understand heterogeneity in FLI1 expression and function

How can surface plasmon resonance be used to characterize FLI1 antibody binding properties?

Surface plasmon resonance (SPR) provides precise characterization of antibody-antigen interactions:

• Binding kinetics determination:

  • SPR experiments using the Biacore T200 instrument with CM5 chips can characterize FLI1 antibody interactions

  • Anti-FLI1 antibody can be immobilized onto the sensor surface using standard amine coupling chemistry

  • Binding kinetics can reveal the association (ka) and dissociation (kd) rate constants, as well as the equilibrium dissociation constant (KD)

• Demonstrated binding properties:

  • A recently developed EWS::FLI1 monoclonal antibody showed remarkable binding affinity with KD of 300 nM for full-length recombinant EWS::FLI1

  • The same antibody demonstrated even stronger binding (KD of 20 pM) to the immunization peptide

• Competitive binding assays:

  • SPR can confirm specificity through peptide competition studies

  • Research showed that full-length EWS::FLI1 could be displaced by specific peptides in binding to the antibody

  • This approach helps determine the precise epitope recognized by the antibody

• Experimental considerations:

  • Buffer composition is critical (HBS-P: 10 mM Hepes pH 7.4, 150 mM NaCl, 0.05% surfactant P20)

  • Addition of 1% DMSO and 0.1% glycerol can improve protein stability during analysis

  • Calculate theoretical Rmax values based on capture response values and molecular weights

What are the latest developments in creating specific antibodies for EWS::FLI1 fusion proteins?

Recent advances have improved the detection and targeting of EWS::FLI1 fusion proteins:

• Novel monoclonal antibody development:

  • Researchers have successfully created a mouse-derived monoclonal antibody from a renewable hybridoma that recognizes EWS::FLI1 with high specificity

  • This antibody demonstrates multimodal utility across various molecular biology applications

  • The development addresses a critical need for stably sourced high-affinity antibodies specific to EWS::FLI1

• Cross-reactive antibodies with clinical value:

  • The EPR3864 antibody cross-reacts with both ERG and FLI1, enabling detection of both EWSR1::FLI1 and EWSR1::ERG fusion proteins

  • This antibody detected 89% of cases with confirmed EWSR1::FLI1 and 100% of cases with EWSR1::ERG gene fusions

  • The dual reactivity provides clinical utility in identifying Ewing sarcoma regardless of fusion partner

• Antibody-based therapeutic strategies:

  • Novel antibodies are being explored not only as diagnostic tools but as potential therapeutic agents

  • Research suggests that targeting FLI1 could have therapeutic implications beyond Ewing sarcoma

  • Recent findings revealed a C1GALT1-dependent mechanism promoting EWSR1::FLI1 expression, which can be inhibited pharmacologically with itraconazole

• Application-specific optimization:

  • New antibodies are validated across multiple applications including Western blot, immunohistochemistry, immunofluorescence, and co-immunoprecipitation

  • Peptide competition assays confirm specificity of newer antibodies

  • Surface plasmon resonance characterization provides quantitative binding parameters

What are the most common technical issues with FLI1 antibodies and their solutions?

Researchers frequently encounter several challenges when working with FLI1 antibodies:

• Weak or absent signal:

  • Problem: Nuclear proteins like FLI1 can be difficult to extract and detect

  • Solution: Use specialized nuclear extraction protocols and verify expression level in your sample type

  • Approach: For FFPE samples, optimize antigen retrieval conditions (consider extending time or using different pH buffers)

  • Consideration: Some FLI1 antibodies detect only 80% of Ewing sarcoma cases , so negative results should be interpreted with caution

• Non-specific bands in Western blot:

  • Problem: Multiple bands observed at unexpected molecular weights

  • Solution: Use peptide competition to identify specific bands

  • Approach: Compare with positive controls (Jurkat cells show bands at ~51-53 kDa for wild-type FLI1)

  • Consideration: EWS::FLI1 fusion proteins appear at higher molecular weights (65-75 kDa), and multiple fusion types exist

• Background staining in immunohistochemistry:

  • Problem: Diffuse or non-nuclear staining pattern

  • Solution: Optimize blocking conditions and antibody dilution

  • Approach: Use biotin-free detection systems to avoid endogenous biotin interference

  • Consideration: Remember that endothelial cells and small lymphocytes naturally express FLI1

• Inconsistent co-immunoprecipitation results:

  • Problem: Variable protein interaction detection

  • Solution: Optimize lysis conditions to preserve nuclear protein complexes

  • Approach: Use crosslinking for transient interactions

  • Consideration: Include appropriate controls (IgG, input, known interaction partners)

How can different fixation and extraction methods affect FLI1 antibody performance?

Sample preparation significantly impacts FLI1 antibody performance:

• Tissue fixation effects:

  • Formalin fixation: Most FLI1 antibodies work with FFPE tissues, but require heat-mediated antigen retrieval

  • Frozen sections: Generally provide better epitope preservation but may have lower morphological quality

  • Fixation duration: Overfixation can mask epitopes, while underfixation may compromise morphology

  • Recommendation: Standardize fixation protocols (10% neutral buffered formalin for 24-48 hours) for consistent results

• Cell preparation for immunocytochemistry:

  • Paraformaldehyde (4%): Provides good balance between epitope preservation and structural integrity

  • Methanol/acetone: Can improve nuclear protein detection but may disrupt some epitopes

  • Recommendation: Test multiple fixation methods when optimizing for a new antibody

• Protein extraction for Western blot/IP:

  • RIPA buffer: May not efficiently extract nuclear transcription factors like FLI1

  • Nuclear extraction kits: Significantly improve detection of nuclear FLI1

  • Detergent considerations: Too harsh detergents may disrupt protein-protein interactions

  • Recommendation: Use specialized nuclear extraction protocols with protease and phosphatase inhibitors

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval: Often necessary for FFPE tissues

  • pH variations: Try both citrate (pH 6.0) and EDTA (pH 9.0) buffers

  • Duration: May need extended retrieval times (20-40 minutes) for nuclear antigens

  • Recommendation: Perform systematic optimization with different retrieval conditions

How can researchers validate the specificity of FLI1 antibodies for their particular application?

Thorough validation ensures reliable and reproducible results:

• Genetic validation approaches:

  • siRNA/shRNA knockdown: Observe reduction in signal with FLI1-targeted knockdown

  • CRISPR/Cas9 knockout: Provides definitive negative control

  • Overexpression systems: Test detection sensitivity and specificity

  • Recommendation: Include genetic controls whenever possible, especially when characterizing new antibodies

• Peptide competition studies:

  • Method: Pre-incubate antibody with immunizing peptide before application

  • Expected result: Specific signal should be blocked while non-specific background remains

  • Controls: Use irrelevant peptides as negative controls

  • Application: Particularly valuable for Western blot and IHC validation

• Multi-method confirmation:

  • Orthogonal detection: Confirm findings using different detection methods

  • Multiple antibodies: Use antibodies targeting different epitopes

  • Molecular methods: Correlate protein detection with mRNA expression

  • Recommendation: Never rely on a single antibody or method for critical findings

• Sample panel validation:

  • Positive controls: Jurkat cells, Ewing sarcoma cell lines (TC32, A4573)

  • Negative controls: HEK cells for EWS::FLI1, neuroblastoma and alveolar rhabdomyosarcoma tissues

  • Tissue panel: Test across multiple tissue types to confirm expected expression pattern

  • Recommendation: Include appropriate controls in every experiment

How are FLI1 antibodies contributing to targeted therapeutic development for Ewing sarcoma?

FLI1 antibodies are instrumental in advancing novel therapeutic approaches:

• Mechanism elucidation:

  • Antibodies help identify and validate key pathways and interactions for therapeutic targeting

  • Recent research using these tools discovered that C1GALT1 promotes EWSR1::FLI1 expression through O-glycosylation of Smoothened (SMO), stabilizing it and stimulating the Hedgehog pathway

  • This pathway directly activates EWSR1::FLI1 transcription and represents a therapeutically targetable mechanism

• Drug screening and validation:

  • FLI1 antibodies enable high-throughput screening to identify compounds that reduce EWS::FLI1 levels

  • This approach identified itraconazole, an FDA-approved anti-fungal agent that inhibits C1GALT1, reduces EWSR1::FLI1 levels in ES cell lines, and suppresses growth of ES xenografts in mice

  • Antibodies provide critical tools for mechanism validation in these studies

• Immunotherapy approaches:

  • Studies revealed FLI1's unexpected role in immune evasion mechanisms

  • FLI1 orchestrates the expression of CBP and STAT1, facilitating chromatin accessibility and transcriptional activation of IDO1 in response to T cell-released IFN-γ

  • Inhibiting FLI1 can obstruct this immunosuppressive pathway, potentially enhancing immune checkpoint therapy

• Direct targeting strategies:

  • While transcription factors like EWS::FLI1 are traditionally considered "undruggable," understanding their regulation offers new approaches

  • Identifying factors that promote EWSR1::FLI1 expression provides indirect targeting opportunities

  • FLI1 antibodies are essential for validating these approaches in preclinical models

What is the role of FLI1 in alternative splicing regulation, and how do antibodies help study this function?

Recent discoveries highlight FLI1's complex role in splicing regulation:

• Splicing modulation by EWS::FLI1:

  • EWS::FLI1 alters the splicing of many mRNA isoforms, but the role of this activity in oncogenesis has been poorly understood

  • Recent research demonstrated that EWS::FLI1 modulates alternative splicing of ARID1A, revealing novel oncogenic function through the BAF complex

  • This creates a feed-forward cycle where EWS::FLI1 promotes splicing of ARID1A-L, which then reciprocally stabilizes EWS::FLI1 protein

• Antibody applications in splicing research:

  • Western blotting with FLI1 antibodies enables detection of alternatively spliced protein isoforms

  • Co-immunoprecipitation identifies interactions with splicing factors such as PRPF8, SFPQ, hnRNPK, and SRSF3

  • Immunofluorescence demonstrates co-localization of EWS::FLI1 with splicing proteins

• Methodological approaches:

  • RNA immunoprecipitation (RIP) combined with FLI1 antibodies identifies RNA targets

  • CLIP-seq (Cross-linking immunoprecipitation with sequencing) maps direct RNA binding sites

  • Sequential IP or proximity ligation assays reveal interactions with splicing machinery

• Therapeutic implications:

  • Understanding these splicing mechanisms opens new therapeutic avenues

  • Splicing modulators could potentially disrupt the EWS::FLI1-ARID1A regulatory circuit

  • FLI1 antibodies provide essential tools for validating such approaches

How can researchers optimize chromatin immunoprecipitation protocols for FLI1 and EWS::FLI1?

ChIP studies with FLI1 antibodies require specific optimization:

• Crosslinking optimization:

  • Standard formaldehyde crosslinking (1%, 10 minutes) works for most applications

  • For protein-protein interactions, consider dual crosslinking (DSG followed by formaldehyde)

  • Crosslinking time may need optimization for nuclear transcription factors

• Chromatin preparation:

  • Sonication conditions should yield 200-500 bp fragments

  • Verify sonication efficiency by agarose gel electrophoresis

  • Use specialized buffers for nuclear transcription factors

• Antibody selection and validation:

  • Test multiple antibodies targeting different epitopes

  • Validate with known target genes before genome-wide studies

  • Consider the epitope location relative to DNA binding domain

• Controls and analysis:

  • Input samples are essential for normalization

  • IgG negative controls establish background signal

  • For EWS::FLI1, consider ChIP with antibodies to both EWS and FLI1 portions

  • Include positive control loci known to be bound by FLI1/EWS::FLI1

• Advanced applications:

  • ChIP-seq reveals genome-wide binding patterns

  • ChIP-SICAP identifies chromatin-associated protein partners

  • Sequential ChIP confirms co-occupancy with other factors